Fierce Biotech August 15, 2024
Turnstone Biologics is narrowing the focus of phase 1 trials of its lead tumor-infiltrating lymphocyte (TIL) therapy, with cutaneous melanoma and breast cancer no longer in the mix.
The program, dubbed TIDAL-01, has been undergoing two phase 1 trials, including the STARLING study evaluating the therapy for the treatment of breast cancer, colorectal cancer and uveal melanoma. Meanwhile, an investigator-sponsored trial with the H. Lee Moffitt Cancer Center and Research Institute has been focused on cutaneous and non-cutaneous melanomas.
In a second-quarter earnings release yesterday, Turnstone said its clinical development strategy for TIDAL-01 is now focused on “three high unmet medical need indications including colorectal cancer, head and neck cancer and uveal melanoma.”
“In doing so, [we] have deprioritized cutaneous...
Today's Sponsors
Today's Sponsor